Logo Logo
Help
Contact
Switch Language to German

Gabriel, Kathrin; Heinzerling, Lucie ORCID logoORCID: https://orcid.org/0000-0001-5718-3643; Baumgarten, Louisa von ORCID logoORCID: https://orcid.org/0000-0002-6634-0927; Subklewe, Marion ORCID logoORCID: https://orcid.org/0000-0001-9154-9469 und Kobold, Sebastian ORCID logoORCID: https://orcid.org/0000-0002-5612-4673 (2026): The role of cytokines in cytokine release syndrome (CRS) after CAR T cell therapy. In: Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, Vol. 1873, No. 3, 120115 [PDF, 2MB]

[thumbnail of 1-s2.0-S016748892600011X-main.pdf]
Preview
Creative Commons Attribution
Published Version

Abstract

Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment landscape for hematological malignancies. However, cytokine release syndrome (CRS) remains a common and potentially severe toxicity, significantly affecting patient safety and requiring intensive clinical management. This review provides a focused synthesis on the role of cytokines in CRS after CAR T cell therapy, integrating recent mechanistic insights with clinical implications. We delineate the cellular and molecular pathways involving key cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6), interferon γ (IFN-γ), tumor necrosis factor α (TNF-α) and granulocyte-macrophage colony-stimulating factor (GM-CSF), describing their sources, downstream signaling events, and effects on target tissues. By bridging basic cytokine biology with clinical aspects and therapeutic strategies, this review aims to provide a comprehensive framework for understanding the role of cytokines in CRS pathophysiology, ultimately supporting the development of safer and more effective CAR T cell therapies.

Actions (login required)

View Item View Item